Lewandowski K, Zawilska K
Kliniki Hematologii Akademii Medycznej, Poznaniu.
Pol Arch Med Wewn. 1993 May;89(5):424-30.
A 62-year-old woman with a 8-month-history of recurrent deep and superficial vein thrombosis developed multiple areas of skin necrosis during warfarin treatment initiation. Routine coagulation tests did not revealed any abnormalities. Protein C plasma activity and concentration were significantly decreased (59.9% and 63.3% of the normal value, respectively). Antithrombin III and protein S (total and free) content were in the normal range. Initially, the adjusted dosage of standard heparin and fresh frozen plasma was administered. Thereafter, the treatment with low doses of oral anticoagulant (acenocoumarol) was reinstalled simultaneously with Protein C Concentrate (Immuno, Vienna) intravenous administration. After six days of the oral anticoagulation the therapeutic value of prothrombin time was obtained and administration of Protein C Concentrate could have been discontinued. No adverse reactions and post-transfusions complications were observed.
一名62岁女性,有8个月复发性深静脉和浅静脉血栓形成病史,在开始使用华法林治疗期间出现多处皮肤坏死。常规凝血试验未发现任何异常。蛋白C血浆活性和浓度显著降低(分别为正常值的59.9%和63.3%)。抗凝血酶III和蛋白S(总含量和游离含量)在正常范围内。最初,给予标准肝素和新鲜冰冻血浆的调整剂量。此后,在静脉注射蛋白C浓缩物(免疫制品,维也纳)的同时,重新开始低剂量口服抗凝剂(醋硝香豆素)治疗。口服抗凝治疗6天后,获得了凝血酶原时间的治疗值,蛋白C浓缩物的给药本可以停止。未观察到不良反应和输血后并发症。